Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FGBQ5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,584.13 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The delivery order, issued on December 15, 2025, with an ultimate completion date of January 7, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion, multi-award vehicle designed to provide pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally through 2036.
DMS Pharmaceutical Group Inc. serves as a critical regional pharmaceutical supplier within the broader $30.3 billion PPV-G GEN V acquisition strategy, which authorizes the company to fulfill firm fixed-price delivery orders for a comprehensive range of pharmaceuticals including branded and generic prescription drugs, biologics, vaccines, and medical consumables. The contractor's product portfolio and recent delivery order activity demonstrate substantial capability in supplying specialized pharmaceutical products including immunosuppressants and biologic agents such as Stelara to military healthcare facilities worldwide, with no identified subcontractor relationships in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FGBQ5?
SPE2DR26FGBQ5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FGBQ5 worth?
The government has obligated $16,584 on SPE2DR26FGBQ5.
Is contract SPE2DR26FGBQ5 an order under another contract?
Yes. SPE2DR26FGBQ5 is a delivery order under SPE2DR25D9315, an indefinite delivery contract.
Was contract SPE2DR26FGBQ5 competed?
The extent of competition for SPE2DR26FGBQ5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award